Patents by Inventor Asser Sloth Andersen
Asser Sloth Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9732137Abstract: A semi-recombinant method for the production of GLP-1 analogues and derivatives with non-proteogenic amino acids in the N-terminal part combining the use of recombinant expression techniques and chemical peptide synthesis.Type: GrantFiled: December 22, 2008Date of Patent: August 15, 2017Assignee: Novo Nordisk A/SInventors: Jesper Færgeman Lau, Asser Sloth Andersen, Paw Bloch, Jesper Lau, Patrick William Garibay, Thomas Kruse, Inga Sig Nielsen Nørby, Claus Ulrich Jessen, Caspar Christensen, Jens Christian Norrild
-
Patent number: 9056921Abstract: The invention is related to a method for making human insulin analogs by culturing an fungi cell comprising a DNA vector encoding a precursor for human insulin analog, wherein the said precursor comprises a connecting peptide flanked with cleavage sites at both junctions with the A- and the B-chain of the insulin peptide, respectively said cleavage sites being cleaved within the fungi cell allowing the cell to secrete high amount of correctly processed, mature two chain human insulin analog to the culture media.Type: GrantFiled: August 15, 2006Date of Patent: June 16, 2015Assignee: Novo Nordisk A/SInventors: Asser Sloth Andersen, Lars Hojlund Christensen
-
Patent number: 8815541Abstract: The invention provides an improved method for producing polypeptides with a C-terminal glycine in a yeast transformant being characterized in having a non functional KEX1 gene. The method is in particular well suited to produce polypeptides with an aromatic amino acid residue attached to the C-terminal glycine. The yeast strain may have further non-functional protease genes selected from PEP4, YPS1, MKCI, YPS3, YPS5, YPS6, YPS7, PRB1, STE13 and KEX2.Type: GrantFiled: November 25, 2010Date of Patent: August 26, 2014Assignee: Novo Nordisk A/SInventors: Asser Sloth Andersen, Inger Lautrup-Larsen, Per Noergaard
-
Patent number: 8518668Abstract: The invention is related to a method for making mature human insulin or an analogue thereof by culturing a fungi cell comprising a DNA sequence encoding a precursor for human insulin or an analogue of human insulin which precursor comprises the B-chain of human insulin or an analogue thereof, the A-chain of human insulin or an analogue thereof and a C-peptide linking the B-chain and the A-chain together thereof, wherein the C-peptide comprises at least one Kex2 cleavage site and an amino acid sequence attached at one end to the C-terminal amino acid residue in the B-chain and at the other end to the Kex2 site which amino acid sequence will facilitate a more efficient Kex2 cleavage within the fungi cell. The C-terminal extension of the B-chain may furthermore be capable of subsequently being cleaved off from the C-terminal amino acid residue in the B-chain by means of a carboxypeptidase activity either within the fungi cell or subsequently in the culture medium.Type: GrantFiled: September 26, 2007Date of Patent: August 27, 2013Assignee: Novo Nordisk A/SInventors: Per Nørgaard, Asser Sloth Andersen
-
Publication number: 20120282653Abstract: The invention provides an improved method for producing polypeptides with a C-terminal glycine in a yeast transformant being characterized in having a non functional KEX1 gene. The method is in particular well suited to produce polypeptides with an aromatic amino acid residue attached to the C-terminal glycine. The yeast strain may have further non-functional protease genes selected from PEP4, YPS1, MKCI, YPS3, YPS5, YPS6, YPS7, PRB1, STE13 and KEX2.Type: ApplicationFiled: November 25, 2010Publication date: November 8, 2012Applicant: Novo Nordisk A/SInventors: Asser Sloth Andersen, Inger Lautrup-Larsen, Per Noergaard
-
Publication number: 20110111460Abstract: The invention is related to a method for making human insulin analogues by culturing an fungi cell comprising a DNA vector encoding a precursor for human insulin analogue, wherein the said precursor comprises a connecting peptide flanked with cleavage sites at both junctions with the A- and the B-chain of the insulin peptide, respectively said cleavage sites being cleaved within the fungi cell allowing the cell to secrete high amount of correctly processed, mature two chain human insulin analogue to the culture media.Type: ApplicationFiled: August 15, 2006Publication date: May 12, 2011Applicant: NOVO NORDISK A/SInventors: Asser Sloth Andersen, Lars Hojlund Christensen
-
Publication number: 20100317057Abstract: A semi-recombinant method for the production of GLP-1 analogues and derivatives with non-proteogenic amino acids in the N-terminal part combining the use of recombinant expression techniques and chemical peptide synthesis.Type: ApplicationFiled: December 22, 2007Publication date: December 16, 2010Applicant: NOVO NORDISK A/SInventors: Jesper Faergeman Lau, Asser Sloth Andersen, Paw Bloch, Jesper Lau, Patrick William Garibay, Thomas Kruse, Inga Sig Nielsen Nørby, Claus Ulrich Jessen, Caspar Christensen, Jens Christian Norrild
-
Publication number: 20100184133Abstract: The invention is related to a method for making mature human insulin or an analogue thereof by culturing a fungi cell comprising a DNA sequence encoding a precursor for human insulin or an analogue of human insulin which precursor comprises the B-chain of human insulin or an analogue thereof, the A-chain of human insulin or an analogue thereof and a C-peptide linking the B-chain and the A-chain together thereof, wherein the C-peptide comprises at least one Kex2 cleavage site and an amino acid sequence attached at one end to the C-terminal amino acid residue in the B-chain and at the other end to the Kex2 site which amino acid sequence will facilitate a more efficient Kex2 cleavage within the fungi cell. The C-terminal extension of the B-chain may furthermore be capable of subsequently being cleaved off from the C-terminal amino acid residue in the B-chain by means of a carboxypeptidase activity either within the fungi cell or subsequently in the culture medium.Type: ApplicationFiled: September 26, 2007Publication date: July 22, 2010Applicant: Novo Nordisk A/SInventors: Per Norgaard, Asser Sloth Andersen
-
Publication number: 20090170750Abstract: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.Type: ApplicationFiled: October 15, 2008Publication date: July 2, 2009Applicant: Novo Nordisk A/SInventors: Thomas Borglum Kjeldsen, Asser Sloth Andersen, Morten Schlein, Anders Robert Sorensen, Peter Madsen
-
Publication number: 20090130086Abstract: The present invention concerns variant factor XIII, wherein the rate of activation of said variant by thrombin is faster than for wild type FXIII. Methods for enhancing fibrin clot formation, pharmaceutical compositions and the use for the manufacture of medicaments wherein the variant factor XIII is applied are disclosed.Type: ApplicationFiled: February 27, 2006Publication date: May 21, 2009Applicant: Novo Nordisk Health Care AGInventors: Rasmus Roejkjaer, Asser Sloth Andersen, Marianne Kjalke, Ole Hvilsted Olsen, Henning Ralf Stennicke
-
Patent number: 6869930Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ?-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the ?-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.Type: GrantFiled: September 17, 1999Date of Patent: March 22, 2005Assignee: Novo Nordisk A/SInventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Sloth Andersen, Jan Markussen
-
Patent number: 6861237Abstract: A process for producing high amount of proteins or polypeptides in yeast is disclosed. The process makes use of the CIT1 yeast promoter or a functional part or variant thereof. Examples of polypeptides which are expressed in high yields are insulin or insulin analogues or GLP1.Type: GrantFiled: November 30, 2001Date of Patent: March 1, 2005Assignee: Novo Nordisk A/SInventors: Asser Sloth Andersen, Ivan Diers
-
Publication number: 20040110664Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the &egr;-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the &egr;-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.Type: ApplicationFiled: March 12, 2002Publication date: June 10, 2004Inventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Sloth Andersen, Jan Markussen
-
Publication number: 20020151472Abstract: A trefoil factor peptide.Type: ApplicationFiled: December 7, 2001Publication date: October 17, 2002Inventors: Lars Thim, Soren E. Bjorn, Asser Sloth Andersen, Steen Seier Poulsen
-
Patent number: 6011007Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the .epsilon.-amino group of Lys.sup.B29 ; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the .epsilon.-amino group of Lys.sup.B29 has a lipophilic substituent; and any Zn.sup.2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and Phe.sup.B1 is present, then the insulin derivative is always present as a Zn.sup.2+ complex.Type: GrantFiled: November 20, 1997Date of Patent: January 4, 2000Assignee: Novo Nordisk A/SInventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Sloth Andersen, Jan Markussen
-
Patent number: 5750497Abstract: The present invention relates to human insulin derivatives having a protracted profile of action in which the A21 and B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the E-amino group of Lys.sup.B29 ; (b) any amino acid residue which can be coded by the genetic code except Lys, Arg and Cys, in which case a lipophilic substituent is bound to the E-amino group of Lys.sup.B29 ; or (c) deleted, in which case a lipophilic substituent is bound to the E-amino group of LyS.sup.B29 ; and any Zn.sup.2+ complexes thereof; provided that when the B30 amino acid residue is Thr or Ala, the A21 and B3 amino acid residues are both Asn and Phe.sup.B1 is present, then the insulin derivative is a Zn.sup.2 + complex.Type: GrantFiled: March 8, 1995Date of Patent: May 12, 1998Assignee: Novo Nordisk A/SInventors: Svend Havelund, John Halstr.o slashed.m, Ib Jonassen, Asser Sloth Andersen, Jan Markussen